Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance regulatory pathways for cannabis-containing and cannabis-derived products
FDA rules could have grave consequences for the CBD industry unless stakeholders are informed, compliant and engaged in policy. Here’s a call to action.
Details